Hyperglycemia in aneurysmal subarachnoid hemorrhage: A potentially modifiable risk factor for poor outcome

65Citations
Citations of this article
78Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Hyperglycemia after aneurysmal subarachnoid hemorrhage (aSAH) occurs frequently and is associated with delayed cerebral ischemia (DCI) and poor clinical outcome. In this review, we highlight the mechanisms that cause hyperglycemia after aSAH, and we discuss how hyperglycemia may contribute to poor clinical outcome in these patients. As hyperglycemia is potentially modifiable with intensive insulin therapy (IIT), we systematically reviewed the literature on IIT in aSAH patients. In these patients, IIT seems to be difficult to achieve in terms of lowering blood glucose levels substantially without an increased risk of (serious) hypoglycemia. Therefore, before initiating a large-scale randomized trial to investigate the clinical benefit of IIT, phase II studies, possibly with the help of cerebral blood glucose monitoring by microdialysis, will first have to improve this therapy in terms of both safety and adequacy. © 2010 ISCBFM All rights reserved.

Cite

CITATION STYLE

APA

Kruyt, N. D., Biessels, G. J., Devries, J. H., Luitse, M. J. A., Vermeulen, M., Rinkel, G. J. E., … Roos, Y. B. (2010, September). Hyperglycemia in aneurysmal subarachnoid hemorrhage: A potentially modifiable risk factor for poor outcome. Journal of Cerebral Blood Flow and Metabolism. https://doi.org/10.1038/jcbfm.2010.102

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free